Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cellular Adaptation IV: Dysplasia and Metaplasia01:24

Cellular Adaptation IV: Dysplasia and Metaplasia

DysplasiaDysplasia refers to abnormal changes in the size, shape, and organization of mature cells, characterized by pleomorphism, nuclear abnormalities, and increased mitotic activity. It commonly affects epithelial tissues, including the cervix, gastrointestinal tract, respiratory mucosa, and endometrium. Although it may occur alongside hyperplasia, dysplasia is not a true adaptive response but a preneoplastic change with potential to progress to cancer.When confined above the basement...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lymphomatoid Papulosis With T-cell Receptor-Gamma Delta Expression: A Clinicopathologic Case-series of 26 Patients of an Underrecognized Immunophenotypic Variant of Lymphomatoid Papulosis.

The American journal of surgical pathology·2024
Same author

Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates.

Human pathology·2023
Same author

Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates.

Human pathology·2023
Same author

ALK+ hyaline vascular Castleman disease: a new kid on the block.

Histopathology·2022
Same author

Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee.

Journal of cutaneous pathology·2021
Same author

Secondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients.

Journal of cutaneous pathology·2021

Related Experiment Video

Updated: Jul 3, 2026

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
08:01

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow

Published on: November 4, 2016

Blastic Plasmacytoid Dendritic Cell Neoplasm.

Antonio Subtil1

  • 1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

Journal of Cutaneous Pathology
|July 1, 2026
PubMed
Summary

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive cancer. This review covers its diagnosis, histopathology, and differential diagnosis to improve early detection.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematopoietic neoplasm originating from immature plasmacytoid dendritic cells.
  • Previously known by various names including CD4+/CD56+ hematodermic neoplasm and blastic NK-cell leukemia/lymphoma.
  • Frequently involves skin and bone marrow, with diagnosis often relying on skin biopsy due to the commonality of cutaneous presentation.

Purpose of the Study:

  • To review the histopathologic, immunohistochemical, and molecular findings of BPDCN.
  • To discuss the current diagnostic criteria for BPDCN.
  • To differentiate BPDCN from other conditions like acute myeloid leukemia and reactive plasmacytoid dendritic cell hyperplasia.

Main Methods:

  • Review of histopathologic findings in BPDCN.
Keywords:
blasticdendritic cellneoplasmplasmacytoidskin

More Related Videos

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
13:34

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors

Published on: March 17, 2014

Related Experiment Videos

Last Updated: Jul 3, 2026

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
08:01

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow

Published on: November 4, 2016

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
13:34

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors

Published on: March 17, 2014

  • Analysis of immunohistochemical markers relevant to BPDCN diagnosis.
  • Examination of molecular data associated with BPDCN.
  • Comparison with differential diagnoses including myeloid neoplasms and reactive conditions.

    • Main Results:

    • BPDCN diagnosis relies on a combination of specific histopathologic and immunohistochemical features.
    • Diagnostic criteria for BPDCN have evolved with better understanding of its cell of origin.
    • Distinguishing BPDCN from acute myeloid leukemia with similar immunophenotypes and reactive hyperplasia is crucial.

    Conclusions:

    • Accurate diagnosis of BPDCN requires comprehensive evaluation of histopathologic, immunohistochemical, and molecular data.
    • Awareness of BPDCN's varied presentations and potential diagnostic challenges is essential for timely diagnosis.
    • Understanding the differential diagnosis aids in appropriate patient management and treatment strategies.